| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology |
Robert H. Lurie Comprehensive Cancer Center [J. M. S., H. L., V. C. J.] and Department of Surgery [D. J. B.], Northwestern University Medical School, Chicago, Illinois 60611, and Signal Pharmaceuticals, San Diego, California 92121 [J. W. Z.]
The active metabolite of tamoxifen, 4-hydroxytamoxifen (4-OHT), is used
in the laboratory for mechanistic studies of antiestrogen action. This
compound binds to the estrogen receptor 
(ER) and silences
activating function 2 (AF2) in the ligand binding domain, but
activating function 1 (AF1) at the other end of the ER remains
constitutive and is considered to be ligand independent. Amino acid
D351 in the ligand binding domain appears to be critical for
interactions with the antiestrogenic side chain of antiestrogens. We
have devised an assay to evaluate the biological activity of 351 mutant
ERs and antiestrogens at the transforming growth factor
(TGF) gene in situ (J. I. MacGregor
Schafer et al., Cancer Res., 59:
4308–4313, 1999). The substitution of glycine for aspartate at
position 351 results in the conversion of the 4-OHT:ER complex from
estrogen-like to completely antiestrogenic. In cells stably expressing
D351G ER, the ER retains responsiveness to estradiol (E2)
and also retains antiestrogenic responsiveness to both raloxifene and
ICI 182,780. The relative binding affinity of E2 for D351G
ER (0.77 ± 0.17 x 10-9
M) is comparable with wild-type ER (0.42 ± 0.08 x 10-9 M). In addition,
the D351G ER retains the ability to bind SRC-1 in the presence of
E2, thus D351G ER AF2 activity has not been compromised. We
also used a cell line stably expressing an ER with a triple mutation in
helix 12 (D538A, E542A, and D545A) that ablated AF2 activity, which
resulted in decreased effects of E2, suggesting that both
AF1 and AF2 activity are required for maximal estrogen activity in
MDA-MB-231 cells. Interestingly, the triple mutation also completely
reduced the estrogen-like actions of 4-OHT. We propose that a specific
mutation at amino acid 351 can allosterically silence AF1 in the
4-OHT:ER complex by either preventing the binding of coactivators or
encouraging the binding of a corepressor molecule. We suggest that the
4-OHT-specific site responsible for estrogen-like actions can be
referred to as AF2b. This binding site would consist of at least four
carboxylic acids at amino acids 351 and 538, 542 and 545 in helix 12 to
permit coactivator docking for gene activation. The AF2b site is
distinct from AF2 for E2 action. Further studies will
provide insight into the estrogen-like actions of tamoxifen in select
tissues and breast tumors and identify a significant mechanism of drug
resistance to tamoxifen.
This article has been cited by other articles:
|
|
 |
|
  V. C. Jordan SERMs: Meeting the Promise of Multifunctional Medicines J Natl Cancer Inst, March 7, 2007; 99(5): 350 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Dayan, M. Lupien, A. Auger, S. I. Anghel, W. Rocha, S. Croisetiere, J. A. Katzenellenbogen, and S. Mader Tamoxifen and Raloxifene Differ in Their Functional Interactions with Aspartate 351 of Estrogen Receptor {alpha} Mol. Pharmacol., August 1, 2006; 70(2): 579 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Fowler, N. M. Solodin, C. C. Valley, and E. T. Alarid Altered Target Gene Regulation Controlled by Estrogen Receptor-{alpha} Concentration Mol. Endocrinol., February 1, 2006; 20(2): 291 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Lewis, K. Meeke, C. Osipo, E. A. Ross, N. Kidawi, T. Li, E. Bell, N. S. Chandel, and V. C. Jordan Intrinsic Mechanism of Estradiol-Induced Apoptosis in Breast Cancer Cells Resistant to Estrogen Deprivation J Natl Cancer Inst, December 7, 2005; 97(23): 1746 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ring and M. Dowsett Mechanisms of tamoxifen resistance Endocr. Relat. Cancer, December 1, 2004; 11(4): 643 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Herynk and S. A. W. Fuqua Estrogen Receptor Mutations in Human Disease Endocr. Rev., December 1, 2004; 25(6): 869 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Osipo, H. Liu, K. Meeke, and V. C. Jordan The Consequences of Exhaustive Antiestrogen Therapy in Breast Cancer: Estrogen-Induced Tumor Cell Death Experimental Biology and Medicine, September 1, 2004; 229(8): 722 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Pearce, H. Liu, I. Radhakrishnan, M. Abdelrahim, S. Safe, and V. C. Jordan Interaction of the Aryl Hydrocarbon Receptor Ligand 6-Methyl-1,3,8-trichlorodibenzofuran with Estrogen Receptor {alpha} Cancer Res., April 15, 2004; 64(8): 2889 - 2897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Liu, E.-S. Lee, C. Gajdos, S. T. Pearce, B. Chen, C. Osipo, J. Loweth, K. McKian, A. De Los Reyes, L. Wing, et al. Apoptotic Action of 17{beta}-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo J Natl Cancer Inst, November 5, 2003; 95(21): 1586 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bentrem, J. E. Fox, S. T. Pearce, H. Liu, S. Pappas, D. Kupfer, J. W. Zapf, and V. C. Jordan Distinct Molecular Conformations of the Estrogen Receptor {alpha} Complex Exploited by Environmental Estrogens Cancer Res., November 1, 2003; 63(21): 7490 - 7496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. V. Jensen and V. C. Jordan The Estrogen Receptor: A Model for Molecular Medicine Clin. Cancer Res., June 1, 2003; 9(6): 1980 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Mishra, A. Mazumdar, R. K. Vadlamudi, F. Li, R.-A. Wang, W. Yu, V. C. Jordan, R. J. Santen, and R. Kumar MICoA, a Novel Metastasis-associated Protein 1 (MTA1) Interacting Protein Coactivator, Regulates Estrogen Receptor-{alpha} Transactivation Functions J. Biol. Chem., May 23, 2003; 278(21): 19209 - 19219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Pearce, H. Liu, and V. C. Jordan Modulation of Estrogen Receptor alpha Function and Stability by Tamoxifen and a Critical Amino Acid (Asp-538) in Helix 12 J. Biol. Chem., February 21, 2003; 278(9): 7630 - 7638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Liu, W.-C. Park, D. J. Bentrem, K. P. McKian, A. D. L. Reyes, J. A. Loweth, J. M. Schafer, J. W. Zapf, and V. C. Jordan Structure-Function Relationships of the Raloxifene-Estrogen Receptor-alpha Complex for Regulating Transforming Growth Factor-alpha Expression in Breast Cancer Cells J. Biol. Chem., March 8, 2002; 277(11): 9189 - 9198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. JORDAN The Past, Present, and Future of Selective Estrogen Receptor Modulation Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 72 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. JORDAN Chemoprevention with Antiestrogens: The Beginning of the End for Breast Cancer: Daniel G. Miller Lecture Ann. N.Y. Acad. Sci., December 1, 2001; 952(1): 60 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan, S. Gapstur, and M. Morrow Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease J Natl Cancer Inst, October 3, 2001; 93(19): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Greenberger, T. Annable, K. I. Collins, B. S. Komm, C. R. Lyttle, C. P. Miller, P. G. Satyaswaroop, Y. Zhang, and P. Frost A New Antiestrogen, 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), Inhibits the Growth of Tamoxifen-sensitive and -resistant Tumors and Is Devoid of Uterotropic Effects in Mice and Rats Clin. Cancer Res., October 1, 2001; 7(10): 3166 - 3177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan, J. M. Schafer, A. S. Levenson, H. Liu, K. M. Pease, L. A. Simons, and J. W. Zapf Molecular Classification of Estrogens Cancer Res., September 1, 2001; 61(18): 6619 - 6623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan Selective Estrogen Receptor Modulation: A Personal Perspective Cancer Res., August 1, 2001; 61(15): 5683 - 5687. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Schafer, E.-S. Lee, R. C. Dardes, D. Bentrem, R. M. O'Regan, A. De Los Reyes, and V. C. Jordan Analysis of Cross-Resistance of the Selective Estrogen Receptor Modulators Arzoxifene (LY353381) and LY117018 in Tamoxifen-stimulated Breast Cancer Xenografts Clin. Cancer Res., August 1, 2001; 7(8): 2505 - 2512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Liu, E.-S. Lee, A. D. L. Reyes, J. W. Zapf, and V. C. Jordan Silencing and Reactivation of the Selective Estrogen Receptor Modulator-Estrogen Receptor {{alpha}} Complex Cancer Res., May 1, 2001; 61(9): 3632 - 3639. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. J. Bentrem, R. C. Dardes, H. Liu, J. MacGregor-Schafer, J. W. Zapf, and V. C. Jordan Molecular Mechanism of Action at Estrogen Receptor {{alpha}} of a New Clinically Relevant Antiestrogen (GW7604) Related to Tamoxifen Endocrinology, February 1, 2001; 142(2): 838 - 846. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
